Gene therapy for malignant glioma

Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Glioblastoma multiforme represents the most common primary malignant tumor of the adult CNS. Unfortunately, the median survival after surgical intervention alone is less than 6 months and the addition of radiotherapy can extend this time to only 9 months. Consequently, efforts aimed at developing new therapies have focused on new treatment strategies that specifically target tumor cells and spare normal cells. One such modality, gene therapy, has shown promise in the spectrum of agents utilized against brain tumors. This review highlights the principles of gene therapy and discusses the results of recent clinical trials in which gene therapy has been employed against malignant brain tumors.

Original languageEnglish (US)
Pages (from-to)479-488
Number of pages10
JournalExpert Review of Neurotherapeutics
Issue number4
StatePublished - Apr 2006


  • Brain tumor
  • Gene therapy
  • Glioma
  • Immunotherapy
  • Viral vectors

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Gene therapy for malignant glioma'. Together they form a unique fingerprint.

Cite this